5XS2 Stock Overview
LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
LexaGene Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.084 |
| 52 Week High | CA$0.21 |
| 52 Week Low | CA$0.041 |
| Beta | 2.25 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -37.37% |
| 3 Year Change | -84.62% |
| 5 Year Change | -89.60% |
| Change since IPO | -50.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5XS2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.8% | -0.6% |
| 1Y | -37.4% | -0.9% | 4.9% |
Rentabilidad frente al sector: 5XS2 obtuvo unos resultados inferiores a los del sector German Medical Equipment , que el año pasado arrojó un rendimiento del -2.5%.
Rentabilidad vs. Mercado: 5XS2 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.
Price Volatility
| 5XS2 volatility | |
|---|---|
| 5XS2 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 5XS2ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 5XS2 en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 33 | Jack Regan | https://www.lexagene.com |
LexaGene Holdings Inc. Fundamentals Summary
| 5XS2 fundamental statistics | |
|---|---|
| Market cap | €10.13m |
| Earnings (TTM) | -€7.90m |
| Revenue (TTM) | €96.51k |
104.9x
P/S Ratio-1.3x
P/E RatioIs 5XS2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5XS2 income statement (TTM) | |
|---|---|
| Revenue | US$104.27k |
| Cost of Revenue | US$757.46k |
| Gross Profit | -US$653.19k |
| Other Expenses | US$7.89m |
| Earnings | -US$8.54m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | -626.46% |
| Net Profit Margin | -8,189.91% |
| Debt/Equity Ratio | 66.4% |
How did 5XS2 perform over the long term?
See historical performance and comparison